LA-ADTRAN
15.8.2024 14:01:35 CEST | Business Wire | Press release
Adtran today announced that PhireLink has deployed its open and intelligent fiber access technology to bring high-quality broadband to some of Louisiana’s most underserved rural communities. The deployment features Adtran’s Mosaic One software-as-a-service and its Intellifi® connected home solution to support a robust end-user experience. Using Adtran’s AI-driven platform, PhireLink is rapidly scaling a highly efficient, future-facing network capable of delivering critical public services, such as remote learning and telemedicine, and stimulating economic growth across the region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815958625/en/
Adtran’s networking technology is helping PhireLink deliver high-speed broadband to rural communities across Louisiana. (Photo: Business Wire)
“We selected Adtran for its open, scalable technology. Our new solution helps us bring dependable, high-speed broadband to more rural communities across Louisiana,” said Glen F. Post, III, CEO of PhireLink. “Working in close collaboration with Adtran’s team, we are not just constructing a network. We’re taking a crucial step towards bridging the digital divide, providing the broadband access needed to invigorate local economies and drive sustained improvements in quality of life.”
Mosaic One empowers PhireLink to enhance operational efficiency, minimize the need for on-site visits, and effectively engage with communities by utilizing materials tailored to local market needs. The end-to-end Combo PON solution also features Adtran’s scalable 10Gbit/s optical line terminal and its SDX 600 Series optical network terminals. What’s more, Adtran’s connected home solution, Intellifi®, is being harnessed in combination with Adtran’s SDG 800 Series Wi-Fi 6 gateways to provide a comprehensive in-home Wi-Fi experience. PhireLink’s customer service representatives can use the platform to resolve connectivity issues remotely, further streamlining operations and ensuring an exceptional customer experience.
“Bridging the digital divide isn’t just a case of deploying the latest and greatest hardware and software. You also need to work closely with clients to overcome challenges unique to each deployment. This is where Adtran excels. We listen to what our clients need and respond with tailored solutions that get the best out of our innovation and give subscribers a great user experience,” commented John Scherzinger, GM of Americas sales at Adtran. “Working closely with PhireLink, we’ve ensured more people in the Slidell area have access to fast and reliable fiber-based internet. But it doesn’t end there. Our Intellifi® cloud-managed Wi-Fi platform enables subscribers to gain better control, personalize and secure their Wi-Fi networks.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
About PhireLink
PhireLink is a broadband internet service provider delivering high-quality, high-speed internet across rural America. At PhireLink, we’re more than just an internet provider — we’re neighbors, dedicated to bringing the power of high-speed connectivity to every corner of the communities we serve. We're driven by one simple goal: level the playing field and ensure everyone, no matter where they live, has access to the limitless opportunities the internet provides. To learn more, visit PhireLink.com.
Published by
ADTRAN Holdings, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240815958625/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom